Transfusion-transmitted babesiosis in Ontario: first reported case in Canada.
Babesiosis has only recently been reported in Canada, but a number of transfusion-transmitted cases of this infection have been reported from the United States. We present a case of transfusion-transmitted babesiosis that occurred in Canada. Canadian physicians must consider babesiosis in the differential diagnosis of patients who experience fever or a hemolytic reaction after blood transfusion. Prompt recognition and treatment are important, because Babesia infections can be severe or fatal in certain risk groups. Better strategies to prevent transfusion-transmitted babesiosis are required.
Kain
K C
KC
Centre for Travel and Tropical Medicine, Division of Infectious Diseases, Department of Medicine, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ont.
Jassoum
S B
SB
Fong
I W
IW
Hannach
B
B
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001404:Babesiosis / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D001782:Blood Donors; D002981:Clindamycin / Q000627:therapeutic use; D017707:Erythrocyte Transfusion / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009864:Ontario; D011803:Quinine / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000962:Antimalarials; D002981:Clindamycin; D011803:Quinine